BioCentury | Aug 29, 2019
Distillery Techniques

STAT3-based gene signature to predict response to glioblastoma targeted therapy

...Tang, Duke-NUS Graduate Medical School, Singapore; National Cancer Centre Singapore, Singapore email: carol_tang@nni.com.sg Claire Quang Agency for Science Technology and Research Duke-NUS Graduate Medical School National...
BioCentury | Apr 12, 2018
Translation in Brief

Viral variant vaccine

...to the development of a safe live attenuated Zika vaccine.” Nature Communications (2018) Mary Romeo, Staff Writer Duke-NUS Graduate Medical School Interferon...
BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

...online Dec. 19, 2017 doi:10.1038/s41467-017-02287-5 CONTACT: Sang Hyun Lee, Duke-NUS Medical School, Singapore email: sanghyun.lee@duke-nus.edu.sg Hongjiang Li Duke-NUS Graduate Medical School Phosphatidylinositol-5-phosphate...
BioCentury | Nov 15, 2017
Preclinical News

Researchers identify IL-11 as new target for cardiovascular fibrosis

...A study published in Nature by researchers at Duke-NUS Graduate Medical School and colleagues showed that inhibiting IL-11 prevented...
...clinical trials of a lead antibody within the next two years to treat fibrotic diseases. Jennie Walters Duke-NUS Graduate Medical School IL-11 Interleukin-11...
BioCentury | Oct 4, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: September 2017

...and mouse studies suggest inhibiting ZNF395 could help treat clear cell renal cell carcinoma (ccRCC). Duke-NUS Graduate Medical School...
BioCentury | Sep 20, 2017
Distillery Therapeutics

Cancer

...Disc. ; published online Sept. 11, 2017 doi:10.1158/2159-8290.CD-17-0375 CONTACT: Patrick Tan, Duke-NUS Graduate Medical School, Singapore email: gmstanp@duke-nus.edu.sg Claire Quang Duke-NUS Graduate Medical School Zinc...
BioCentury | Jul 20, 2015
Clinical News

ETC-159: Phase I started

...a 2009 deal between A*STAR’s Experimental Therapeutics Centre, Drug Discovery and Development (D3) unit and Duke-NUS Graduate Medical School...
...the Prime Minister’s Office in Singapore that funds R&D initiatives, jointly established D3 in 2012. Duke-NUS Graduate Medical School...
BioCentury | Apr 16, 2015
Distillery Therapeutics

Therapeutics: Casein kinase 1α (CSNK1A; CK1-α)

...al J. Clin. Invest.; published online Mar. 23, 2015 doi: 10.1172/JCI78018 CONTACT: David M. Virshup, Duke-NUS Graduate Medical School...
BioCentury | Mar 20, 2014
Translation in Brief

Translational tidbits

...project to provide a molecular map to guide therapy in systemic autoimmune diseases ImaginAb Inc. Duke-NUS Graduate Medical School...
BioCentury | Feb 17, 2014
Company News

ImaginAb, Duke-NUS Graduate Medical School, National Research Foundation cancer, endocrine/metabolic news

...the National University of Singapore (NUS) established Duke-NUS in 2005. ImaginAb Inc. , Inglewood, Calif. Duke-NUS Graduate Medical School...
Items per page:
1 - 10 of 14
BioCentury | Aug 29, 2019
Distillery Techniques

STAT3-based gene signature to predict response to glioblastoma targeted therapy

...Tang, Duke-NUS Graduate Medical School, Singapore; National Cancer Centre Singapore, Singapore email: carol_tang@nni.com.sg Claire Quang Agency for Science Technology and Research Duke-NUS Graduate Medical School National...
BioCentury | Apr 12, 2018
Translation in Brief

Viral variant vaccine

...to the development of a safe live attenuated Zika vaccine.” Nature Communications (2018) Mary Romeo, Staff Writer Duke-NUS Graduate Medical School Interferon...
BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

...online Dec. 19, 2017 doi:10.1038/s41467-017-02287-5 CONTACT: Sang Hyun Lee, Duke-NUS Medical School, Singapore email: sanghyun.lee@duke-nus.edu.sg Hongjiang Li Duke-NUS Graduate Medical School Phosphatidylinositol-5-phosphate...
BioCentury | Nov 15, 2017
Preclinical News

Researchers identify IL-11 as new target for cardiovascular fibrosis

...A study published in Nature by researchers at Duke-NUS Graduate Medical School and colleagues showed that inhibiting IL-11 prevented...
...clinical trials of a lead antibody within the next two years to treat fibrotic diseases. Jennie Walters Duke-NUS Graduate Medical School IL-11 Interleukin-11...
BioCentury | Oct 4, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: September 2017

...and mouse studies suggest inhibiting ZNF395 could help treat clear cell renal cell carcinoma (ccRCC). Duke-NUS Graduate Medical School...
BioCentury | Sep 20, 2017
Distillery Therapeutics

Cancer

...Disc. ; published online Sept. 11, 2017 doi:10.1158/2159-8290.CD-17-0375 CONTACT: Patrick Tan, Duke-NUS Graduate Medical School, Singapore email: gmstanp@duke-nus.edu.sg Claire Quang Duke-NUS Graduate Medical School Zinc...
BioCentury | Jul 20, 2015
Clinical News

ETC-159: Phase I started

...a 2009 deal between A*STAR’s Experimental Therapeutics Centre, Drug Discovery and Development (D3) unit and Duke-NUS Graduate Medical School...
...the Prime Minister’s Office in Singapore that funds R&D initiatives, jointly established D3 in 2012. Duke-NUS Graduate Medical School...
BioCentury | Apr 16, 2015
Distillery Therapeutics

Therapeutics: Casein kinase 1α (CSNK1A; CK1-α)

...al J. Clin. Invest.; published online Mar. 23, 2015 doi: 10.1172/JCI78018 CONTACT: David M. Virshup, Duke-NUS Graduate Medical School...
BioCentury | Mar 20, 2014
Translation in Brief

Translational tidbits

...project to provide a molecular map to guide therapy in systemic autoimmune diseases ImaginAb Inc. Duke-NUS Graduate Medical School...
BioCentury | Feb 17, 2014
Company News

ImaginAb, Duke-NUS Graduate Medical School, National Research Foundation cancer, endocrine/metabolic news

...the National University of Singapore (NUS) established Duke-NUS in 2005. ImaginAb Inc. , Inglewood, Calif. Duke-NUS Graduate Medical School...
Items per page:
1 - 10 of 14